Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2334-2341

  Gerber, Bernd ^{a,b,c,d,e,f,g,h,i,j,k}   Von Minckwitz, Gunter ^{a,b,c,d,e,f,g,h,i,j,k}   Stehle, Heinrich ^{a,b,c,d,e,f,g,h,i,j,k}   Reimer, Toralf ^{a,b,c,d,e,f,g,h,i,j,k}   Felberbaum, Ricardo ^{a,b,c,d,e,f,g,h,i,j,k}   Maass, Nikolai ^{a,b,c,d,e,f,g,h,i,j,k}   Fischer, Dorothea ^{a,b,c,d,e,f,g,h,i,j,k}   Sommer, Harald L ^{a,b,c,d,e,f,g,h,i,j,k}   Conrad, Bettina ^{a,b,c,d,e,f,g,h,i,j,k}   Ortmann, Olaf ^{a,b,c,d,e,f,g,h,i,j,k}   Fehm, Tanja ^{a,b,c,d,e,f,g,h,i,j,k}   Rezai, Mahdi ^{a,b,c,d,e,f,g,h,i,j,k}   Mehta, Keyur ^{a,b,c,d,e,f,g,h,i,j,k}   Loibl, Sibylle ^{a,b,c,d,e,f,g,h,i,j,k}  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GBG Forschungs GmbH   (Germany)

^c MARIENHOSPITAL STUTTGART   (Germany)

^d Klinikum Kempten Oberallgau   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h Elisabeth Krankenhaus   (Germany)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k Luisenkrankenhaus   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GEMCITABINE; GOSERELIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; TRASTUZUMAB;

ABORTION; ADULT; AGE; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVARIAN PRESERVATION; OVARY FOLLICLE; OVARY FUNCTION; OVARY INSUFFICIENCY; PHASE 2 CLINICAL TRIAL; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THERAPY DELAY; TREATMENT DURATION; UROGENITAL TRACT DISEASE;

ADULT; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GOSERELIN; HUMANS; MENSTRUATION; MIDDLE AGED; OVARY;

EID: 79959195282     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5704     Document Type: Article

References (34)

1. National Cancer Institute: Surveillance, Epidemiology and End Results: Breast cancer incidence and mortality. www.seer.cancer.gov/statfacts/html/ breast.html
2. Anders CK, Hsu DS, Broadwater G, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324-3330, 2008
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Clarke M, Coates AS, Darby SC, et al: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 371:29-40, 2008
5. Walshe JM, Denduluri N, Swain SM: Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769-5779, 2006 (Pubitemid 46646480)
6. Schover LR: Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26:753-758, 2008
7. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006 (Pubitemid 46655598)
8. Arbeitsgemeinschaft Gynäkologische Onkologie: Diagnosis and treatment of early and metastatic breast cancer. http://www.ago-online.de/index. php?lang=en&site=guidelines
9. Oktem O, Oktay K: A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 67:10159-10162, 2007 (Pubitemid 350070787)
10. Recchia F, Saggio G, Amiconi G, et al: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106:514-523, 2006 (Pubitemid 43157613)
11. Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17:74-78, 2006 (Pubitemid 43033843)
12. Urruticoechea A, Arnedos M, Walsh G, et al: Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 110:411-416, 2008 (Pubitemid 351962592)
13. Badawy A, Elnashar A, El-Ashry M, et al: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 91:694-697, 2009
14. Sonmezer M, Oktay K: Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11:422-434, 2006 (Pubitemid 43788268)
15. Alviggi C, Humaidan P, Howles CM, et al: Biological versus chronological ovarian age: Implications for assisted reproductive technology. Reprod Biol Endocrinol 7:101, 2009
16. Lee S, Kil WJ, Chun M, et al: Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 16:98-103, 2009
17. Petrek JA, Naughton MJ, Case LD, et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051, 2006 (Pubitemid 46638800)
18. Oktay K, Sönmezer M: Questioning GnRH analogs for gonadal protection in cancer patients. Fertil Steril 92:e32, 2009; author reply e34
19. Sverrisdottir A, Nystedt M, Johansson H, at al: Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: Results from a randomized trial. Breast Cancer Res Treat 117:561-567, 2009
20. Han HS, Ro J, Lee KS, et al: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115:335-342, 2009
21. Del Mastro L, Boni L, Michelotti A, et al: Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 28:15s, 2010 (suppl; abstr 528)
22. Ismail-Khan R, Minton S, Cox, C, et al: Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GNRH agonist (triptorelin) during chemotherapy. J Clin Oncol 26:12s, 2008 (suppl; abstr 524)
23. Leonard RC, Adamson D, Anderson R, et al: The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 590)
24. Blumenfeld Z: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryo-preservation of embrya, oocytes, or ovaries. Oncologist 12:1044-1054, 2007
25. Oktay K, Briggs D, Gosden RG: Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 82:3748-3751, 1997 (Pubitemid 27509366)
26. Gerber B, Dieterich M, Müller H, et al: Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat 108:1-7, 2008 (Pubitemid 351623232)
27. Vanhuyse M, Fournier C, Bonneterre J: Chemotherapy-induced amenorrhea: Influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 16:1283-1288, 2005 (Pubitemid 41158472)
28. Cruz MR, Prestes JC, Gimenes DL, et al: Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: A systematic review. Fertil Steril 94:138-133, 2009
29. Colgan TJ, Murphy J, Cole DE, et al: Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283-1289, 2001 (Pubitemid 32917122)
30. Lutchman SK, Muttukrishna S, Stein RC, et al: Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96:1808-1816, 2007
31. Anders C, Marcom PK, Peterson B, et al: A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26: 286-295, 2008 (Pubitemid 351329008)
32. Su HI, Sammel MD, Green J, et al: Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116:592-599, 2010
33. Partridge AH, Ruddy KJ, Gelber S, et al: Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94:638-644, 2010
34. Yu B, Douglas N, Ferin MJ, et al: Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116:2099-2105, 2010